ABEC Launches ATB-2100 Bioreactor Platform

The single-use, fully automated system is designed for cell expansion from preclinical development through commercial manufacturing.

Updated on Nov. 5, 2026 in Biotech

Single-use translucent bioreactor bag with coiled tubing and hollow-fiber membrane cartridges on a steel frame in a clean white bioprocessing suite.
ABEC has launched its ATB-2100 Advanced Therapy Bioreactor, a single-use, fully closed system designed to expand cells from preclinical development through commercial manufacturing. AI Illustration. Upload story photo >

ABEC, a global provider of engineered solutions for biopharmaceutical manufacturing, has launched its ATB-2100 Advanced Therapy Bioreactor platform. The single-use, fully closed system is built to expand cells across the development-to-commercial pipeline.

Why it matters

Cell expansion is a bottleneck in advanced therapy manufacturing, and a closed, automated single-use platform aims to address it. The launch extends ABEC's product line into cell-based therapy production.

The ATB-2100 supports working volumes from 200mL to 10L with a consistent membrane surface-area-to-volume ratio across that range, according to manufacturer specifications. Independent validation of these performance claims was not included in the announcement.

The players

ABEC

ABEC is a global provider of engineered solutions and services for biopharmaceutical manufacturing, with more than 50 years of innovation in the field.

The details

The ATB-2100 uses proprietary hollow-fiber perfusion membranes that deliver nutrients and gases while removing metabolic waste, in a diffusion-based, low-shear environment. The platform has demonstrated expansion of T-cells, induced pluripotent stem cells, mesenchymal stem cells and other emerging modalities.

Timeline

  1. • November 5, 2026: ABEC announced the commercial launch of the ATB-2100.

Tech Race

Single-use bioreactors have increasingly replaced stainless-steel systems in cell and gene therapy manufacturing because they reduce contamination risk and cleaning validation. The ATB-2100 enters this segment with a fully closed, automated design aimed at scaling cell expansion from preclinical work to commercial production.

For developers and manufacturers of cell-based therapies, the ATB-2100 offers a closed, automated option that may reduce hands-on handling during expansion. Adoption will depend on fit with existing workflows and validation requirements.

The takeaway

Closed, single-use platforms are gaining ground in advanced therapy manufacturing as developers seek to lower contamination risk and scale production. Teams evaluating cell expansion options should compare platform performance data against their own process requirements.

Further reading

Explore more Biotech developments shaping cell and gene therapy manufacturing.

More information

Find ATB-2100 product information on the ABEC website.

Source note: This article includes information reported by The Manila times.